Apellis Pharmaceuticals Inc
NASDAQ:APLS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
US |
|
Medicover AB
OTC:MCVEF
|
SE |
|
W
|
Wing Tai Properties Ltd
HKEX:369
|
HK |
|
GAMCO Investors Inc
OTC:GAMI
|
US |
|
Orell Fuessli AG
SIX:OFN
|
CH |
|
F
|
Focus Dynamics Group Bhd
KLSE:FOCUS
|
MY |
|
Cineverse Corp
NASDAQ:CNVS
|
US |
|
E
|
ESR Group Ltd
F:3K6
|
HK |
|
Vivani Medical Inc
NASDAQ:VANI
|
US |
|
R
|
Richelieu Hardware Ltd
TSX:RCH
|
CA |
Wall Street
Price Targets
APLS Price Targets Summary
Apellis Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
APLS
is 34.17 USD
with a low forecast of 18.18 USD and a high forecast of 57.75 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is APLS's stock price target?
Price Target
34.17
USD
According to Wall Street analysts, the average 1-year price target for
APLS
is 34.17 USD
with a low forecast of 18.18 USD and a high forecast of 57.75 USD.
What is Apellis Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
6%
The
compound annual growth rate
of Apellis Pharmaceuticals Inc's revenue for the next 3 years is
6%.
What is Apellis Pharmaceuticals Inc's Operating Income forecast?
Projected CAGR
35%
The
compound annual growth rate
of Apellis Pharmaceuticals Inc's operating income for the next 3 years is
35%.
What is Apellis Pharmaceuticals Inc's Net Income forecast?
Projected CAGR
69%
The
compound annual growth rate
of Apellis Pharmaceuticals Inc's net income for the next 3 years is
69%.
